Get the Stockscreener App
406.99
2.61%
-11.91
Madrigal Pharmaceuticals Inc stock is traded at $406.99, with a volume of 301.91K.
It is down -2.61% in the last 24 hours and down -7.91% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$418.90
Open:
$421.64
24h Volume:
301.91K
Relative Volume:
0.86
Market Cap:
$9.00B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-16.20
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-6.38%
1M Performance:
-7.91%
6M Performance:
+29.32%
1Y Performance:
+27.66%
1-Day Range:
$399.00
$430.50
1-Week Range:
$393.61
$435.00
52-Week Range:
$265.00
$463.62
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
405.42 | 9.34B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals (MDGL) Upgraded to Neutral by BofA on R - GuruFocus
Chart based exit strategy for Madrigal Pharmaceuticals Inc.2025 Market Trends & Safe Swing Trade Setups - newser.com
Why Madrigal Pharmaceuticals Inc. (YDO1) stock signals breakout potentialAnalyst Upgrade & Proven Capital Preservation Methods - newser.com
MDGL: B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral | MDGL Stock News - GuruFocus
BofA Upgrades Madrigal Pharmaceuticals to Neutral From Underperform, Price Target is $445 - MarketScreener
Why analysts recommend Madrigal Pharmaceuticals Inc. (YDO1) stock2025 Price Momentum & Community Verified Trade Alerts - newser.com
How Madrigal Pharmaceuticals Inc. stock reacts to global recession fearsJuly 2025 Final Week & Reliable Momentum Entry Alerts - newser.com
Can Madrigal Pharmaceuticals Inc. stock beat market expectations this quarterEarnings Risk Report & Low Risk Profit Maximizing Plans - newser.com
Madrigal Pharmaceuticals Inc. stock trendline breakdownWeekly Risk Summary & Weekly Market Pulse Alerts - newser.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Will Madrigal Pharmaceuticals Inc. stock gain from lower inflationJuly 2025 News Drivers & Daily Profit Maximizing Tips - newser.com
Can Madrigal Pharmaceuticals Inc. stock hit record highs againJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthJuly 2025 Institutional & Weekly High Potential Stock Alerts - newser.com
Statistical indicators supporting Madrigal Pharmaceuticals Inc.’s strengthMarket Risk Report & Daily Stock Momentum Reports - newser.com
How to integrate Madrigal Pharmaceuticals Inc. into portfolio analysis tools2025 Price Targets & AI Forecast Swing Trade Picks - newser.com
Madrigal Pharmaceuticals Inc. stock chart pattern explained2025 Technical Patterns & Risk Managed Investment Signals - newser.com
Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep raising dividendsJuly 2025 Setups & Accurate Trade Setup Notifications - newser.com
Research Analysts Offer Predictions for MDGL FY2025 Earnings - MarketBeat
How to escape a deep drawdown in Madrigal Pharmaceuticals Inc.July 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com
Is it too late to sell Madrigal Pharmaceuticals Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - newser.com
Is Madrigal Pharmaceuticals Inc. trending in predictive chart modelsQuarterly Profit Summary & Long Hold Capital Preservation Tips - newser.com
Madrigal Pharmaceuticals, Inc. (MDGL) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
A Look at Madrigal Pharmaceuticals (MDGL) Valuation Following New Rezdiffra Data to Be Presented at AASLD 2025 - Sahm
What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockExit Strategy Tips & Turn Market Volatility into Wealth - earlytimes.in
Madrigal Pharmaceuticals to Report Third-Quarter 2025 Results on November 4 - MSN
Emerald Mutual Fund Advisers Trust Boosts Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Using RSI to spot recovery in Madrigal Pharmaceuticals Inc.Market Performance Summary & Risk Managed Trade Strategies - newser.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 5.4%Should You Sell? - MarketBeat
Emerald Advisers LLC Acquires 5,199 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Grants Equity Awards to New Employees Under 2025 Inducement Plan - MyChesCo
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by D.A. Davidson & CO. - MarketBeat
How forex fluctuations impact Madrigal Pharmaceuticals Inc. (YDO1) stockTrade Ideas & AI Enhanced Trading Signals - newser.com
Truist Securities Initiates Coverage of Madrigal Pharmaceuticals (MDGL) with Buy Recommendation - MSN
Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? - sharewise.com
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):